- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
FDA Approves Siemens Mobilett Mira Mobile Digital X-Ray System
Siemens Healthcare’s Mobilett Mira, the company’s first mobile digital X-ray system with a wireless detector, has received 510(k) clearance from the U.S. Food and Drug Administration and is now commercially available in the United States.
Siemens Healthcare’s Mobilett Mira, the company’s first mobile digital X-ray system with a wireless detector, has received 510(k) clearance from the U.S. Food and Drug Administration and is now commercially available in the United States.
The Mobilett Mira’s wireless capacity helps with examinations of patients with limited mobility, and its rotating swivel arm helps increase ease-of-use for clinical staff, the company said.
Similar to their mobile X-ray systems, the device has a rotating swivel arm so that, rather than moving the patient around, radiologists and technologists can move the swivel arm instead. Siemens officials said, though, that theirs is the first mobile X-ray device using a wireless detector, which does away with the data cable needed with other such devices.
The Mobilett Mira has 7-megapixel resolution and exposure times shorter than 1 millisecond.
The X-ray swivel arm moves vertically and rotates 90 degrees, integrating electric connection cables. In addition, the company said, the Mobilett Mira is the first mobile X-ray system that can be maintained and updated via remote monitoring. Siemens Remote Services (SRS) regularly provides the system with recommended software updates.
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.
Can MRI-Based AI Bolster Biopsy Decision-Making in PI-RADS 3 Cases?
December 9th 2024In patients with PI-RADS 3 lesion assessments, the combination of AI and prostate-specific antigen density (PSAD) level achieved a 78 percent sensitivity and 93 percent negative predictive value for clinically significant prostate cancer (csPCa), according to research presented at the Radiological Society of North American (RSNA) conference.
